Clearside Biomedical Touts Encouraging Durable Data From Investigational Candidate For Vision Disorder
February 02, 2023 at 13:18 PM EST
Clearside Biomedical Inc(NASDAQ: CLSD) announced results from the Extension Study of its OASIS Phase 1/2a trial of CLS-AX ...